Sector News

Deshpande leaves Achillion, leaving CEO chair free for Truitt

May 2, 2018
Life sciences

Achillion has promoted Joseph Truitt to replace outgoing CEO Milind Deshpande, Ph.D. The change puts the person who has overseen Achillion’s business development and commercial strategy for almost a decade in charge of the biotech as it nears midphase complement factor D data.

Truitt joined Achillion in 2009 after previously working at Viropharma and a Johnson & Johnson unit. Back then, Achillion was an infectious disease player looking to carve out a piece of the hepatitis C market. Gilead put pay to that plan, prompting Deshpande to reposition Achillion as a specialist in complement biology.

That repositioning means the company Truitt is inheriting is significantly different than the one he joined. The big clinical milestones ahead of Achillion 2.0 relate to rare diseases, specifically the renal condition C3 glomerulopathy (C3G) and paroxysmal nocturnal hemoglobinuria (PNH). Achillion expects to have interim phase 2 data in C3G in the third quarter, with an update on a PNH to follow shortly after.

Achillion has set Truitt’s base salary at $560,000, 37% more than his base salary as EVP and COO but less than his predecessor pulled in. Truitt also stands to receive a bonus of up to 55% of his base salary if he hits certain goals. Last year, Truitt received 75% of his maximum possible bonus as reward for his role in Achillion’s business development and the offering of stock held by Johnson & Johnson.

The biotech signaled its intent to hand Truitt more responsibility in February when it gave him the role of president, which was previously held by Deshpande. That move came months after the board signed off on a $26,000 pay bump for Truitt and added EVP to his existing title of COO.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.